565
Views
8
CrossRef citations to date
0
Altmetric
Review

Treatment of pemphigus vulgaris: part 2 – emerging therapies

, &
Pages 1061-1071 | Received 05 Jul 2019, Accepted 23 Sep 2019, Published online: 10 Oct 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Khalaf Kridin & A. Razzaque Ahmed. (2021) The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review. Expert Opinion on Biological Therapy 21:4, pages 443-454.
Read now

Articles from other publishers (6)

Cristina Segú-Vergés, Silvia Caño, Elisabeth Calderón-Gómez, Helena Bartra, Teresa Sardon, Srini Kaveri & José Terencio. (2022) Systems biology and artificial intelligence analysis highlights the pleiotropic effect of IVIg therapy in autoimmune diseases with a predominant role on B cells and complement system. Frontiers in Immunology 13.
Crossref
Erin Somerville, Kurt Gebauer & Andrew Mclean‐Tooke. (2022) Treatment of pemphigus in Australia: Aligning current practises with global recommendations. Australasian Journal of Dermatology 63:2, pages 190-196.
Crossref
Bavleen Kaur, Jenna Kerbrat, Jia Kho, Manreet Kaler, Stefanos Kanatsios & Nicola Cirillo. (2021) Mechanism‐based therapeutic targets of pemphigus vulgaris: A scoping review of pathogenic molecular pathways. Experimental Dermatology 31:2, pages 154-171.
Crossref
V. A. Litvinov. (2021) Peculiarities of Quality of Life in Patients with Pemphigus Vulgaris according to the Results of the Analysis of the SF-36V2 Questionnaires and Dermatological Index of Quality of Life in the Background of Glucocorticosteroid Therapy. Ukraïnsʹkij žurnal medicini, bìologìï ta sportu 6:6, pages 123-133.
Crossref
Maria Luiza Petzl-Erler. (2020) Beyond the HLA polymorphism: A complex pattern of genetic susceptibility to pemphigus. Genetics and Molecular Biology 43:3.
Crossref
Jayachandran Sadaksharam. (2019) Current Therapeutic Modalities of Immunobullous Lesions. Contemporary Clinical Dentistry 10:3, pages 407-409.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.